<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623336</url>
  </required_header>
  <id_info>
    <org_study_id>11/0468</org_study_id>
    <nct_id>NCT01623336</nct_id>
  </id_info>
  <brief_title>BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C</brief_title>
  <acronym>BIP48II/III</acronym>
  <official_title>Safety and Efficacy of BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C: Randomized, Multicentric Study With Blinded Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the noninferiority of BIP48 (48 kDa peginterferon
      alfa-2b) compared to Pegasys ® (40 kDa peginterferon alfa-2a) associated with ribavirin, in
      naive patients with chronic hepatitis C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be an open, multicenter, randomized, controlled phase II - III trial. Patients
      (n = 740) will be randomized (1:1) to receive BIP48 (peginterferon alfa-2b 48kDa) or Pegasys
      ® (peginterferon alfa-2a 40kDa) 180 micrograms ,subcutaneously,once a week,associated with
      ribavirin at a dose 1000-1250 mg, orally, daily. For genotype 1 treatment time will be 48 to
      72 weeks and for genotypes 2 and 3, 24 to 48 weeks. The study's population will be naive
      patients, of both sex, between 18 and 70 years old, with chronic hepatitis C (HCV), genotypes
      1, 2 or 3, from 18 to 25 Brazilian research centers. Diagnostic criteria will be as followed:
      positive anti-HCV and qualitative PCR, liver biopsy showing any degree of fibrosis and at
      least mild inflammatory activity, performed in the last 24 months. The interruption Criteria
      will be: no partial virological response at 12 weeks and positive quantitative PCR at week
      24.The primary outcome will be the rate of sustained virologic response and the secondary
      endpoints will be the quality of life during treatment, frequency of adverse events and
      cost-effectiveness. As a substudy, will be performed a comparative assessment in 24 patients,
      evaluating viral kinetics, pharmacokinetics and pharmacodynamics of repeated doses of both
      alfapeginterferons .
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of sustained virologic response - SVR - measured by PCR at 24 weeks after treatment.</measure>
    <time_frame>HCV PCR will be measured at 24 weeks after the end of therapy (week 48 for genotypes 2 and 3 and week 72 for genotype 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>Clinical exam, blood tests and immunogenicity evaluation will be done twice monthly, in the first month, and then monthly until the end of treatment( week 24 for genotypes 2 and 3 and week 48 for genotype 1).</time_frame>
    <description>Blood tests included: ALT, AST, Creatinine and complete blood count. Anti-interferon immunoglobulin and thyroid-stimulating hormone (TSH) will be measured in the weeks 12, 24, 36, 48, 60 and 72 of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic response at the end of treatment</measure>
    <time_frame>Viral load will be measured at the end of treatment (week 24 for genotypes 2 and 3 and week 48 for genotype 1)</time_frame>
    <description>Viral load will be measured by quantitative PCR at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">740</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Pegasys ®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Pegasys ® (peginterferon alfa-2a 40kDa) at a dose of 180 micrograms, subcutaneously, once a week, associated with ribavirin at a dose 1000-1250 mg,daily. For genotype 1 treatment time is 48 to 72 weeks and for genotypes 2 and 3, 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIP 48 (Peginterferon alfa 2b 48kDA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive BIP 48, 180 micrograms a week, SC, for the same period as Pegasys ®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIP 48 (Peginterferon alfa 2b 48kDA)</intervention_name>
    <description>BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.</description>
    <arm_group_label>Pegasys ®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa 2a 40kDA</intervention_name>
    <description>Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.</description>
    <arm_group_label>Pegasys ®</arm_group_label>
    <other_name>Pegasys ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIP 48 (Peginterferon alfa 2b 48kDA)</intervention_name>
    <description>Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.</description>
    <arm_group_label>BIP 48 (Peginterferon alfa 2b 48kDA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. anti-HCV positive;

          2. viral load of HCV positive;

          3. viral genotypes 1, 2 or 3;

          4. the absence of previous treatment for chronic hepatitis C;

          5. liver biopsy performed in the last 36 months classified by Metavir score as at least
             A1, with any degree of fibrosis ;

          6. age from 18 to 70 years old;

          7. hemoglobin greater than 11 g / dl;

          8. platelet count higher than 75.000/mm3;

          9. neutrophils higher than 1.500/mm3;

         10. use of, at least two contraceptive methods during treatment and up to 36 weeks after
             the last dose of study medication (for male or female subjects in fertile age );

         11. concordance and signing of the informed consent.

        Exclusion Criteria:

          1. decompensated cirrhosis (Child-Pugh score&gt; 6);

          2. history of bleeding gastroesophageal varices;

          3. hemoglobinopathies;

          4. hepatocellular carcinoma;

          5. co-infection with HIV or HBV;

          6. other coexisting chronic liver disease, as autoimmune hepatitis, Wilson disease,
             hemochromatosis, chronic obstructive cholestatic disease or autoimmune disease,
             alcoholic liver disease;

          7. malignancies except basal cell carcinoma in situ or cervix carcinoma;

          8. systemic autoimmune diseases, except compensated autoimmune thyroid diseases ;

          9. uncontrolled seizures;

         10. primary immunodeficiencies;

         11. myelosuppression;

         12. coagulation disorders;

         13. thrombophilias;

         14. thrombopathy ;

         15. decompensated heart failure;

         16. chronic renal failure;

         17. diagnosis of other comorbidity that would compromise the subject's participation in
             the research study as judged by the investigator (eg, neuropsychiatric diseases,
             systemic infection or antibiotic use within 4 weeks, decompensated diabetes mellitus,
             ischemic heart disease, heart failure, respiratory or renal or uncontrolled
             hypertension);

         18. prior organ transplantation, except cornea;

         19. alcohol consumption exceeding 20g/day for women and 40g/dia for men during the past
             six months;

         20. use of illicit drugs in the previous six months;

         21. use of immunosuppressive agents during the previous six months;

         22. pregnancy or lactation;

         23. male research subjects whose sexual partner is pregnant;

         24. previous treatment with IFN or ribavirin in the last 6 months prior to inclusion;

         25. subjects with hypersensibility to IFN alpha and / or any of its components;

         26. subjects with hypersensibility to ribavirin and / or any of its ingredients;

         27. participation in another clinical study in the last 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo D. Picon, Invest</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guilherme B. Sander, Coord</last_name>
    <role>Study Director</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luiz E. Mazzoleni, Coord</last_name>
    <role>Study Director</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>André C. Wortmann, Monitor</last_name>
    <role>Study Chair</role>
    <affiliation>NUCLIMED</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karine M. Amaral, Coordenação</last_name>
    <role>Study Chair</role>
    <affiliation>NUCLIMED</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marisa B. Costa, Sub Coord</last_name>
    <role>Study Chair</role>
    <affiliation>NUCLIMED</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias C. Milbradt, Coord Log.</last_name>
    <role>Study Chair</role>
    <affiliation>NUCLIMED</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Indara C. Saccilotto, Coordenação</last_name>
    <role>Study Chair</role>
    <affiliation>NUCLIMED</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amanda Quevedo, Sub Coord</last_name>
    <role>Study Chair</role>
    <affiliation>NUCLIMED</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daiana V. Gomes, AssitSocial</last_name>
    <role>Study Chair</role>
    <affiliation>NUCLIMED</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valeria Lucia de S. Gil, ASCLIN</last_name>
    <phone>552138827199</phone>
    <email>valeria.lucia@bio.fiocruz.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria de Lourdes de S. Maia, ASCLIN</last_name>
    <phone>552138829479</phone>
    <email>lourdes.maia@bio.fiocruz.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ufrgs/Hcpa</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria de Lourdes S. Maia, ASCLIN</last_name>
      <phone>552138829479</phone>
      <email>mlourdes@bio.fiocruz.br</email>
    </contact>
    <contact_backup>
      <last_name>Vivian Rotman, ASCLIN</last_name>
      <phone>552138829474</phone>
      <email>vivian.rotman@bio.fiocruz.br</email>
    </contact_backup>
    <investigator>
      <last_name>Paulo D. Picon, PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guilherme B. Sander, Coord</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luiz E. Mazzoleni, Coord</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <last_update_submitted>June 15, 2012</last_update_submitted>
  <last_update_submitted_qc>June 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HEPATITIS</keyword>
  <keyword>HEPATITIS C</keyword>
  <keyword>PEGINTERFERON</keyword>
  <keyword>BIOEQUIVALENCE</keyword>
  <keyword>TREATMENT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

